Compare · ELV vs GH
ELV vs GH
Side-by-side comparison of Elevance Health Inc. (ELV) and Guardant Health Inc. (GH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and GH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.37B, about 3.6x GH ($23.68B).
- Over the past year, ELV is up 24.1% and GH is up 186.3% - GH leads by 162.2 points.
- GH has been more active in the news (14 items in the past 4 weeks vs 1 for ELV).
- GH has more recent analyst coverage (25 ratings vs 23 for ELV).
- Company
- Elevance Health Inc.
- Guardant Health Inc.
- Price
- $396.29-0.48%
- $177.34+0.53%
- Market cap
- $86.37B
- $23.68B
- 1M return
- -1.56%
- +3.79%
- 1Y return
- +24.05%
- +186.26%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 1
- 14
- Recent ratings
- 23
- 25
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Latest ELV
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
Latest GH
- Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,274 units (SEC Form 4)
- Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 5,020 units (SEC Form 4)
- Chief Technology Officer Chudova Darya sold $1,377,364 worth of shares (7,738 units at $178.00), decreasing direct ownership by 10% to 70,635 units (SEC Form 4)
- Director Azar Alex M Ii sold $144,550 worth of shares (826 units at $175.00), decreasing direct ownership by 50% to 825 units (SEC Form 4)
- Director Krognes Steve E. sold $1,172,886 worth of shares (6,674 units at $175.74), decreasing direct ownership by 46% to 7,906 units (SEC Form 4)
- Director Tariq Musa converted options into 249 shares and sold $20,300 worth of shares (116 units at $175.00), increasing direct ownership by 1% to 11,449 units (SEC Form 4)
- SEC Form 144 filed by Guardant Health Inc.
- Director Azar Alex M Ii converted options into 1,651 shares (SEC Form 4)
- Chief Information Officer Kalia Kumud sold $632,193 worth of shares (4,000 units at $158.05), decreasing direct ownership by 9% to 39,794 units (SEC Form 4)
- Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening